


RealRate

PHARMACEUTICAL 2022

Amphastar Pharmaceuticals Inc. Rank 33 of 475









PHARMACEUTICAL 2022





Amphastar Pharmaceuticals Inc. Rank 33 of 475

The relative strengths and weaknesses of Amphastar Pharmaceuticals Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Amphastar Pharmaceuticals Inc. compared to the market average is the variable Net Income, increasing the Economic Capital Ratio by 438% points. The greatest weakness of Amphastar Pharmaceuticals Inc. is the variable Cost of Goods Sold, reducing the Economic Capital Ratio by 193% points.

The company's Economic Capital Ratio, given in the ranking table, is 165%, being 441% points above the market average of -276%.

Input Variable	Value in 1000 USD
Assets, Current	318,119
Cost of Goods Sold	238,029
Intangible Assets	0
Liabilities, Current	103,810
Liabilities, Non-Current	40,356
Other Assets	109,166
Other Compr. Net Income	-4,229
Other Expenses	38,116
Other Liabilities	81,841
Other Net Income	14,044
Property and Equipment	244,244
Research and Development	60,932
Revenues	437,768
Selling, General and Administrative Expense	51,434

Output Variable	Value in 1000 USD
Assets	671,529
Liabilities	226,007
Expenses	388,511
Stockholders Equity	445,522
Net Income	63,301
Comprehensive Net Income	61,186
Economic Capital Ratio	165%

